Hematology Practice Questions

Q: A 65-year-old man presents with cyanosis, confusion, and a pulse oximetry reading of 85% despite receiving supplemental oxygen. What is the most likely cause of his hypoxia?

Methemoglobinemia. ***Methemoglobinemia*** - **Cyanosis** and **confusion** in the presence of hypoxia refractory to **supplemental oxygen** suggest **methemoglobinemia** [1]. - In this condition, iron in heme is oxidized to the ferric state, impairing **oxygen binding** and causing a left shift in the oxygen dissociation curve, reducing oxygen delivery to tissues. *Pulmonary embolism* - While pulmonary embolism can cause acute shortness of breath and hypoxia, it typically responds to supplemental oxygen, especially if the ventilation-perfusion mismatch is not severe [2]. - Cyanosis and decreased mental status are usually seen in massive pulmonary embolism, but the **refractoriness to oxygen** is less characteristic than in methemoglobinemia [2]. *Congestive heart failure* - Worsening heart failure can cause hypoxemia due to **pulmonary edema** and impaired gas exchange, often presenting with dyspnea, orthopnea, and crackles. - However, the hypoxia is usually responsive to oxygen supplementation, and severe cyanosis and confusion refractory to oxygen are less typical presentations compared to methemoglobinemia [2]. *Chronic obstructive pulmonary disease* - Patients with severe COPD can have baseline hypoxia and hypercapnia, but the acute development of severe cyanosis and confusion with **hypoxia refractory to oxygen** is more concerning for an alternative cause. - While exacerbations can cause worsened oxygenation, the described clinical picture, particularly the persistence of hypoxia despite oxygen, points away from uncomplicated COPD exacerbation [2].

Q: A 40-year-old woman with a history of systemic lupus erythematosus (SLE) presents with acute onset of dyspnea and pleuritic chest pain. A chest CT shows multiple bilateral pulmonary emboli. What is the most likely underlying cause?

Antiphospholipid syndrome. Detailed assessment of a patient with SLE presenting with acute dyspnea and pleuritic pain involves ruling out common complications. ***Antiphospholipid syndrome*** - Patients with **SLE** have a high prevalence of **antiphospholipid antibodies**, which significantly increase the risk of both arterial and venous **thrombosis**, including **pulmonary emboli** [1]. - The combination of a history of SLE and acute thrombotic events like **pulmonary embolism** makes antiphospholipid syndrome the most likely underlying cause. *Infective endocarditis* - While infective endocarditis can cause septic emboli, typically from vegetations, it usually presents with fever, new heart murmurs, and signs of infection, which are not mentioned in this patient's presentation. - The emboli in infective endocarditis are usually sterile or septic microemboli, rather than large **pulmonary emboli** typically seen in thrombotic disorders. *Pulmonary hypertension* - Pulmonary hypertension can cause dyspnea and chest pain, but it is a consequence of structural or functional changes in the pulmonary vasculature, not a direct cause of acute **pulmonary emboli**. - While chronic recurrent pulmonary emboli can lead to **chronic thromboembolic pulmonary hypertension (CTEPH)**, the acute presentation described points to the emboli themselves as the primary event. *Congestive heart failure* - Congestive heart failure causes dyspnea and can be associated with chest pain, but the primary pathology involves impaired cardiac function leading to fluid overload and pulmonary congestion, not multiple **pulmonary emboli**. - A CT scan showing **pulmonary emboli** specifically points away from congestive heart failure as the primary cause of the acute symptoms in this context.

Q: What is a common early sign of vitamin B12 deficiency?

Glossitis. ***Glossitis*** - **Glossitis**, or inflammation of the tongue, characterized by a **smooth, beefy-red appearance**, is a common early manifestation of vitamin B12 deficiency due to rapid cell turnover in the oral mucosa [1]. - Reduced **erythrocyte production** resulting from B12 deficiency leads to impaired oxygen delivery to tissues, contributing to tongue changes and discomfort. *Jaundice* - **Jaundice** typically occurs in conditions involving increased **bilirubin** levels, such as liver disease or hemolytic anemia, which are not direct or early features of vitamin B12 deficiency. - While **cobalamin deficiency** can cause **hemolysis** leading to inefficient erythropoiesis, overt jaundice is less frequent as an initial sign. *Pallor* - **Pallor**, a pale complexion, is a general sign of **anemia**, which can result from vitamin B12 deficiency [1]. However, it is a less specific early sign than glossitis, as it can occur in many types of anemia. - The anemia associated with B12 deficiency is typically **macrocytic**, characterized by abnormally large red blood cells, which contributes to pallor [2] but may develop gradually. *Peripheral neuropathy* - **Peripheral neuropathy**, involving symptoms like numbness, tingling, or weakness, is a significant neurological manifestation of chronic vitamin B12 deficiency but usually develops later [2]. - Early stages of B12 deficiency often present with more subtle hematological or gastrointestinal signs before neurological damage becomes apparent.

Q: A 55-year-old man presents with fatigue and shortness of breath. Laboratory results reveal normocytic anemia and increased reticulocytes. Which condition is most consistent with these findings?

Hemolytic anemia. ***Hemolytic anemia*** - The presence of **normocytic anemia** along with **increased reticulocytes** indicates the bone marrow is compensating for red blood cell destruction, typical of hemolytic anemia. - Symptoms like **fatigue and shortness of breath** are common due to decreased oxygen-carrying capacity from the anemia. *Pernicious anemia* - This condition typically presents with **macrocytic anemia** and may have neurological symptoms due to vitamin B12 deficiency, differing from normocytic findings. - It is not associated with elevated reticulocyte counts, as red blood cell production is impaired rather than compensatory. *Iron deficiency anemia* [1] - Iron deficiency anemia usually results in **microcytic anemia** and low reticulocyte counts, contrasting with the findings in this patient [1]. - Symptoms may include **fatigue and pallor**, but the laboratory changes do not align with normocytic anemia or increased reticulocytes. *Aplastic anemia* - Aplastic anemia leads to a **pancytopenia** (low blood cell counts across the board) rather than just anemia, with reticulocytes often being **low or absent**. - Symptoms involve severe fatigue and increased susceptibility to infections and bleeding, which differ from isolated anemia symptoms.

Q: A 65-year-old woman presents with progressive fatigue and abdominal discomfort. Imaging reveals massive splenomegaly. A bone marrow aspirate shows myeloid cells with the Philadelphia chromosome. What is the first-line treatment for this condition?

Imatinib. ***Imatinib*** - The presence of the **Philadelphia chromosome** (BCR-ABL fusion gene) in a patient with progressive fatigue, abdominal discomfort, and massive splenomegaly is characteristic of **Chronic Myeloid Leukemia (CML)**. - **Imatinib** is a **tyrosine kinase inhibitor (TKI)** that specifically targets the BCR-ABL protein, making it the highly effective and universally accepted first-line treatment for CML [1]. *All-trans retinoic acid* - **All-trans retinoic acid (ATRA)** is a retinoid derivative used to treat **Acute Promyelocytic Leukemia (APL)**. - It works by inducing differentiation of leukemic promyelocytes but is ineffective for CML. *Hydroxyurea* - **Hydroxyurea** is a myelosuppressive agent used to reduce high white blood cell counts in **CML**, especially in the **blastic phase** or to manage severe symptoms [1]. - While it can control cell counts, it does not target the underlying genetic abnormality (Philadelphia chromosome) and is not considered first-line curative therapy [1]. *Rituximab* - **Rituximab** is a **monoclonal antibody** that targets the **CD20 protein** on B lymphocytes, used in the treatment of **B-cell non-Hodgkin lymphoma** and some autoimmune diseases. - It has no role in the direct treatment of CML, which is a myeloid malignancy [2].

Q: A 32-year-old woman presents with fever, fatigue, jaundice, and anemia. Laboratory results show hemoglobin of 7.5, a high reticulocyte count, and elevated indirect bilirubin. The peripheral smear reveals spherocytes. What is the definitive treatment?

Corticosteroids. Corticosteroids - The presented symptoms (fever, fatigue, jaundice, anemia with high reticulocytes, elevated indirect bilirubin, and spherocytes) are highly suggestive of warm autoimmune hemolytic anemia (AIHA) [1]. - Corticosteroids are the first-line and often definitive treatment, suppressing the immune system and reducing antibody production against red blood cells. Splenectomy - Splenectomy is considered a second-line treatment option if corticosteroids fail or if the patient requires unacceptably high doses for maintenance. - It removes the primary site of red blood cell destruction but is not the initial definitive treatment. Blood transfusion - Blood transfusion is a supportive measure used to manage severe anemia and stabilize the patient, but it does not address the underlying autoimmune process. - While helping with symptoms, it is not a definitive treatment for the autoimmune destruction of red blood cells. Immunosuppressive therapy - While corticosteroids are a type of immunosuppressive therapy, other forms of immunosuppressive therapy (e.g., rituximab, azathioprine, cyclophosphamide) are typically reserved for cases refractory to corticosteroids and splenectomy [2]. - They are not considered the initial definitive treatment for warm AIHA.

Q: In which condition are multiple lytic lesions typically seen?

Multiple myeloma. ***Multiple myeloma*** - Characterized by **solitary lytic bone lesions** [1], often seen on X-rays, indicating areas of bone destruction [1]. - It is associated with **monoclonal proliferation** of plasma cells [1], leading to both osteolytic lesions and hypercalcemia. *Osteoblast* - Involvement of osteoblasts typically leads to **bone formation**, not lytic lesions. - Conditions like **osteosarcoma** may show lytic lesions, but not from osteoblast activity directly. *Mitral stenosis* - Primarily a **valvular heart disease**, leading to **blood flow obstruction**, not associated with lytic bone lesions. - Symptoms are predominantly related to **cardiac function** rather than bone pathology. *Atherosclerosis* - A vascular condition characterized by **plaque formation** within arteries, affecting blood flow but not leading to bone lesions. - It manifests as cardiovascular diseases, not as **osseous lesions**.

Q: What is the first-line treatment for idiopathic thrombocytopenia purpura (ITP)?

Corticosteroids. ***Corticosteroids*** - **Corticosteroids**, such as prednisone or dexamethasone, are the **first-line treatment** for ITP due to their ability to quickly reduce antibody production and improve platelet count by immunosuppression. - They work by **decreasing platelet destruction** in the spleen and improving the integrity of blood vessels. *Blood transfusion* - **Blood transfusions** are not a primary treatment for ITP as they do not address the underlying autoimmune destruction of platelets and donated platelets are rapidly destroyed. - They are reserved for **life-threatening hemorrhage** as a temporary measure to increase platelet count in severe bleeding episodes. *Intravenous immunoglobulins (IVIG)* - **IVIG** is typically used in ITP patients who have **severe bleeding**, are unresponsive to corticosteroids, or require a rapid increase in platelet count for emergent situations. - It works by **blocking Fc receptors** on macrophages, thereby reducing platelet destruction, but is not the initial first-line therapy. *Splenectomy* - **Splenectomy** is considered a **second-line treatment** for ITP, reserved for patients who are refractory to medical therapy or require long-term remission [1]. - It removes the primary site of platelet destruction and antibody production but carries **surgical risks** and is not the initial approach [1].

Q: What is the earliest hematological change following splenectomy?

Leukocytosis and thrombocytosis. Detailed explanation of hematological changes after splenectomy: ***Leukocytosis and thrombocytosis*** - Following splenectomy, there is an increase in **white blood cells (leukocytosis)** and **platelets (thrombocytosis)**, which is the earliest hematological change observed. - This is due to the loss of splenic function, which normally clears excess blood cells from circulation. *Poikilocytosis* - Poikilocytosis refers to the presence of abnormally shaped red blood cells, which typically indicates an underlying **hemolytic anemia** or **nutritional deficiency** [1]. - This change is **not specific** to splenectomy and may take longer to occur post-surgery. *Presence of Heinz bodies* - Heinz bodies indicate the presence of **denatured hemoglobin** often found in conditions like **G6PD deficiency** or **oxidative stress**. - They are **not a direct consequence** of splenectomy and do not appear as an early hematological change. *Evidence of Howell Jolly bodies* - Howell Jolly bodies are remnants of nuclear material in red blood cells, typically seen after splenectomy due to the spleen's role in **removing such bodies**. - However, their appearance is **later on** compared to leukocytosis and thrombocytosis following surgery.

Q: Which of the following is typically not associated with secondary Idiopathic thrombocytopenic purpura?

Rheumatoid arthritis. ***Rheumatoid arthritis*** - While rheumatoid arthritis is an **autoimmune disease**, its association with secondary ITP is statistically **less common** compared to other systemic autoimmune conditions or infections. - ITP is primarily associated with conditions that directly lead to the production of **anti-platelet antibodies** or impair platelet production/survival more significantly. *Systemic lupus erythematosus* - **SLE** is a well-established cause of **secondary ITP** due to its widespread autoimmune activity, including the production of autoantibodies against platelets [1]. - Thrombocytopenia is a common hematologic manifestation of lupus. *Hepatitis C infection* - **Hepatitis C virus (HCV) infection** is strongly associated with secondary ITP, often through immune complex formation and direct effects on platelet survival and production. - HCV can induce the production of **anti-platelet antibodies**. *HIV infection* - **HIV infection** is a frequent cause of secondary ITP, with thrombocytopenia often being one of the earliest hematologic abnormalities. - Mechanisms include **direct viral effects on megakaryocytes**, immune-mediated destruction of platelets, and increased platelet consumption.

Question 1

A 65-year-old man presents with cyanosis, confusion, and a pulse oximetry reading of 85% despite receiving supplemental oxygen. What is the most likely cause of his hypoxia?

Accepted Answer

Methemoglobinemia

Answer

Pulmonary embolism

Answer

Congestive heart failure

Answer

Chronic obstructive pulmonary disease

Question 2

A 40-year-old woman with a history of systemic lupus erythematosus (SLE) presents with acute onset of dyspnea and pleuritic chest pain. A chest CT shows multiple bilateral pulmonary emboli. What is the most likely underlying cause?

Accepted Answer

Antiphospholipid syndrome

Answer

Infective endocarditis

Answer

Pulmonary hypertension

Answer

Congestive heart failure

Question 3

What is a common early sign of vitamin B12 deficiency?

Accepted Answer

Glossitis

Answer

Jaundice

Answer

Pallor

Answer

Peripheral neuropathy

Question 4

A 55-year-old man presents with fatigue and shortness of breath. Laboratory results reveal normocytic anemia and increased reticulocytes. Which condition is most consistent with these findings?

Accepted Answer

Hemolytic anemia

Answer

Iron deficiency anemia

Answer

Pernicious anemia

Answer

Aplastic anemia

Question 5

A 65-year-old woman presents with progressive fatigue and abdominal discomfort. Imaging reveals massive splenomegaly. A bone marrow aspirate shows myeloid cells with the Philadelphia chromosome. What is the first-line treatment for this condition?

Accepted Answer

Imatinib

Answer

All-trans retinoic acid

Answer

Hydroxyurea

Answer

Rituximab

Question 6

A 32-year-old woman presents with fever, fatigue, jaundice, and anemia. Laboratory results show hemoglobin of 7.5, a high reticulocyte count, and elevated indirect bilirubin. The peripheral smear reveals spherocytes. What is the definitive treatment?

Accepted Answer

Corticosteroids

Answer

Splenectomy

Answer

Blood transfusion

Answer

Immunosuppressive therapy

Question 7

In which condition are multiple lytic lesions typically seen?

Accepted Answer

Multiple myeloma

Answer

Mitral stenosis

Answer

Atherosclerosis

Answer

Osteoporosis

Question 8

What is the first-line treatment for idiopathic thrombocytopenia purpura (ITP)?

Accepted Answer

Corticosteroids

Answer

Splenectomy

Answer

Intravenous immunoglobulins (IVIG)

Answer

Blood transfusion

Question 9

What is the earliest hematological change following splenectomy?

Accepted Answer

Leukocytosis and thrombocytosis

Answer

Presence of Heinz bodies

Answer

Evidence of Howell Jolly bodies

Answer

Poikilocytosis

Question 10

Which of the following is typically not associated with secondary Idiopathic thrombocytopenic purpura?

Accepted Answer

Rheumatoid arthritis

Answer

HIV infection

Answer

Systemic lupus erythmatosus

Answer

Hepatitis C infection

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?